ANN ARBOR, Mich., Oct. 28, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announces that it has delivered its latest batch of spider silk silkworm eggs to its production facility in Vietnam.

This delivery marks the first shipment of the Company specialized recombinant spider silk silkworm eggs to Vietnam since the global outbreak of COVID-19. With restrictions on operations and travel in Vietnam now lifting, the Company is able to resume the scale up of spider silk production.

“With our silkworms now delivered, we are moving quickly, resuming production, and working to develop opportunities with apparel brands to bring exciting new products to market,” said CEO and Founder Kim Thompson. “We believe that this delivery puts us back on track with our plans for production and further commercialization opportunities.”

Operations at the Company’s production facility in Vietnam have now resumed and production scale up is underway.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Oct. 15, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announces that it has completed production and genetic screening of its latest batch of spider silk silkworm eggs. These specialized silkworm eggs are now ready for shipment to Vietnam to restart commercial production.

Production operations at the Company’s factory were suspended in March due to a mandatory shutdown, resulting from the global spread of COVID-19. During the COVID-19 quarantine, Kraig Labs’ U.S.-based team focused its efforts on improving the performance and genetics of its Dragon Silk strain of recombinant spider silk silkworms. Kraig Labs’ U.S. operations also used this time to scale up its supply of silkworm eggs to allow for a restart of its operations in Vietnam.

“Our teams have done a fantastic job, making significant progress in our genetics, production readiness, and R&D,” said CEO and Founder, Kim Thompson. “We believe that these silkworm eggs that are now ready for shipment to our factory, represent the future of spider silk production.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., June 29, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), a leading developer of spider silk based fibers, announces that it has completed the development phase of a new program targeting the largest challenge facing global silk production, viral pathogens. As reported in the Journal of Biological Control, volume 31, viral diseases can result in total annual silk production losses of as much as 32%. 

Kraig Labs has developed its first immune-enhancing genetic insert, designed to create disease-resistant silkworms. The Company is now ready for its first round of transgenic creation and resistance testing. This effort was done in a parallel, and complementary, effort to the Company’s groundbreaking program developing high-performance spider silk inspired silk fibers and yarns.

Global silk production is expected to reach USD 17 billion in 2021; the economic impact of eliminating the loss from disease is a multi-billion dollar opportunity. The Company anticipates that its development of a disease resistant silkworm could be licensed across the entire global silk industry.

“Our work to enhance the disease resistance of our silkworms complements and strengths our focus in bringing our recombinant spider silk to market,” said CEO and Founder, Kim Thompson. “We believe that success in this effort will also provide significant opportunities for growth far beyond the reach of Kraig’s in-house production capacity, with licensing applications globally.”

Once proven, the Company expects to merge these disease resistance properties within its existing lines of genetically enhanced recombinant spider silks.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., June 09, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), a leading developer of spider silk based fibers, announces that it has submitted its formal application to list the Company’s common stock on the Nasdaq Capital Market.

“After significantly strengthening our technology, business model, and corporate governance, to position Kraig Labs for future growth, an uplisting to the Nasdaq Capital Market is the natural evolution for the Company and our shareholders.  We are pleased to be working on the process with the Maxim Group for this raise of up to $24 million,” stated Kim Thompson, Kraig Biocraft Laboratories’ CEO and Chairman of the Board. “Kraig Labs has been blessed with loyal shareholders, and we expect that moving to Nasdaq will raise the Company’s visibility and expand our shareholder family.”

The Company’s application for uplisting, to the Nasdaq Capital Market, is subject to approval based on the ability to meet Nasdaq requirements. The Company intends to satisfy all of the applicable listing requirements, however, no assurance can be given that this application will be approved. During the Nasdaq review process, the Company’s common stock will continue to trade on the OTCQB under its current symbol, KBLB. 

Management believes that listing on the Nasdaq Capital Markets will expand opportunities for the Company’s recombinant spider silk materials within the technical textiles markets.  Analysts forecast that the global technical textile market was valued at nearly $235 billion in 2017, and is projected to reach about $335 billion by 2025, growing at a CAGR of 4.5% from 2018 to 2025.

The Company has filed a registration statement with the Securities and Exchange Commission on Form S-1, which has not yet become effective, and plans to conduct an offering of its securities in order to raise sufficient funds to meet the Nasdaq requirements as well as fund its continued growth and operations. No securities may be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. For a copy of the draft registration statement, please contact ir@kraiglabs.com or visit www.kraiglabs.com/sec-filings/. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., May 18, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”) announces that the Company’s Board of Directors held its first meeting with its four new members-elect in attendance.  During this meeting, management briefed the board on the Company’s plans for 2020 expansion and growth.  The scheduled increases in spider silk production for 2020 and the role of the new “knock-in/knock-out” technology were also discussed.

The Company’s expansion of its Board of Directors is intended to strengthen its corporate governance and to directly address the requirements for listing on a national exchange. 

The new members-elect are expected to be formally nominated and seated as voting members within the next sixty days. The expanded board brings a wealth of experience in international manufacturing operations, corporate finance, and accounting.  The board will help the Company navigate what management expects to be a period of significant growth.

“The Kraig Labs Board of Directors is being expanded, with three independent directors and with the appointment of Jon Rice, the Company’s COO, to satisfy the governance criteria for listing on a national exchange,” said Chairman and CEO, Kim Thompson.  This very positive upgrade in our corporate governance has been part of our growth plan since our last shareholder meeting, in 2019.  As the Company grows, so should the level of oversight.”

Thompson continued, “Our first meeting with the expanded board was very productive, including discussions of specific committee appointments.  The new members were selected for the unique strengths that each brings to our operations, as we work to significantly expand our production.  Our management team is looking forward to the formal appointment of these new members, in the very near future, and I want to thank each of them for their work and enthusiasm.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., May 12, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”) announces that Company is preparing to transfer production back to Prodigy Textiles, its Vietnamese subsidiary.  During the COVID-19 lockdown, when the Company opted to furlough its non-essential staff, the Company shifted its spider silk production operations focus to its US research facility.  The Company is now ready to transition the majority of its production back to Vietnam as soon as the silkworm rearing cycle allows.

During this pandemic, the Company has continued to advance and strengthen its production operations.  Through vigorous testing of its Dragon Silk^TM and Monster Silk® lines, the Company identified its best performing and hardy silkworms ideally suited for large scale production. This milestone is the result of a dedicated effort by its U.S. staff, going far beyond standard material performance testing.  This first production cycle of 2020, at the Company’s Vietnam factory, will utilize these top performing transgenics, forming a solid foundation for the continued 2020 production scale up.

The Company anticipates rapid scale up of its recombinant spider silk and will use this year’s first production run to ship materials are dedicated to fulfill an outstanding order, by one of the Company development partners. The following production runs will be to address fiber requests made by additional potential development partners and to grow the breeding population.

“As we finish preparations for the 2020 production season, the future of Kraig Labs, has never looked brighter,” said COO Jon Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., April 16, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk based fibers, announced, at a press conference held after today’s market close, that it successfully developed a new technology platform, based on a non-CRISPR gene editing knock-in knock-out technology. Other than the silkworm’s remaining specifically desired native silk protein elements, the Company is now able to produce nearly pure spider silk.

The new technology has a purity rate that is about ten times greater than Dragon Silk, a fiber that the Company developed with its previous tools. Dragon Silk has already demonstrated to be tougher than many fibers used in bullet proof vests and the Company expects that the increased spider silk purity, created using this new approach, will yield materials beyond those capabilities.

This new system utilizes the Company’s eco-friendly and cost effective silkworm production system, which is significantly more advanced than any of the competing methods.

Press Conference highlights include:

• Generation II Spider Silk Technology- Essentially pure spider silk.
• Generation III Spider Silk Technology- More specific customization.
• The Company’s knock-in knock-out technology allows Kraig Labs to work with very complex protein sequences in silkworm, which are about four times more complex than published technologies.
• Dr. Trevor Kane, the Company’s Chief Scientific Officer, stated that his team is already working on producing even larger, more complex, constructs, based on the Darwin’s bark spider.  
• Ambitious immunity boosting program will benefit not only the Company’s proprietary transgenics, but will help strengthen production for the mundane silk market, which is a $5 billion a year industry.
• The New Technology, which is the result of over ten years of effort, hits the target of one of the Company’s primary technological goals and opens the door for large scale US production.

This new technology has applications and implications far beyond material performance. The Company is now well underway, and rapidly advancing, its efforts to enhance its silkworm technology to allow for large scale US production. The Company has already begun the validation process for the first of these new transgenics and anticipates US production to be possible as early as 2022 or 2023.

Interested parties are invited to view the press conference rebroadcast at https://youtu.be/NPg_7ACrBjI 

This ground breaking announcement does not affect the Company’s current work, at its overseas production facility, to ramp up Dragon Silk and Monster Silk, as these fibers are designed to address their own markets.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., April 16, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), the leading developer of spider silk based fibers, announces the Company will an online press conference, today at 4:30 p.m. Eastern Time, to introduce a game changing Spider Silk technological breakthrough.  This conference will open to all press, stakeholders and interested parties, via a live streaming broadcast at www.kblbinvestors.com/live.

The webcast will be accessible on most operating systems and browsers and a replay will be available, following the event, within the Investor Relations section of the Company’s web site.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., April 13, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), the leading developer of spider silk based fibers, announces that Kim Thompson, the Company’s CEO and Founder, and Kenneth Le, the President of Prodigy Textiles, will be making a personal donation, on behalf of all Kraig and Prodigy Employees, to the community of Quang Nam Province Vietnam.  Quang Nam is where the Company maintains a production facility and where most of the employees of Prodigy, Kraig’s wholly owned subsidiary, reside. The financial gift is being made in light of the global financial and public health issues facing our world. 

Through this donation, direct food aid will be provided to roughly 600 families in the farming cooperatives and villages in Quang Nam.  Each family will receive 10kg of rice, noodles, cooking oil, fish sauce, and other items.  Additional financial aid being provided will be coordinated by Mr. Le, in partnership with local officials, to ensure that other critical needs in the community are met.

In mid-March the Company took the voluntary step to furlough non-essential workers, as a precautionary step.  To minimize the financial impact of this decision, on furloughed staff, Company management has committed to keep these workers on the payroll through at least the end of April.  Today’s announcement is a further expansion of the Company’s commitment to our team members and their communities.

“I am thankful for the opportunity to personally support our valued team members,” said Thompson.  “As we all work together to combat coronavirus, our team at Kraig Labs continues to make significant progress in critical aspects of our business model.  Having laid a solid foundation, our teams in the US and Vietnam are preparing the Company to exit this stronger than ever.   I believe that this will be a break out year for Kraig Labs, so the least our management team can do is share a little of that good fortune and spread it forward to the communities that are our home.  I want to thank Mr. Ken Le for his generosity, his bold vision and his friendship.  These monies will not come from the corporate treasury.”

“Later this week we will be revealing a major research and development milestone from within our own laboratories,” continued Thompson.  “We view this breakthrough as the most significant and impactful development in our laboratories in more than seven years.  Our scientists are working tirelessly in our pursuit of commercializing nature’s toughest fibers, spider silk. I encourage those who are interested to join us for this live event.”

On April 16 at 4:30pm ET, the Company will be revealing a significant scientific breakthrough in spider silk technology during an online press conference.  All interested parties can view this live event by going to www.kblbinvestors.com

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com 

ANN ARBOR, Mich., April 06, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), the leading developer of spider silk based fibers, announces that Kim Thompson, the Company’s CEO and Founder, has accepted an invitation to speak at this year’s SynBio Markets conference to be held in Amsterdam, Netherlands beginning November 3^rd.

SynBio Markets focus is synthetic biology solutions to commercial and sustainability challenges.  The international conference is designed to showcase the most innovative synthetic biology companies.

“We are delighted to be welcoming Mr. Thompson to the conference and have such a leader in innovation as Kraig Biocraft Laboratories joining the speaker lineup in Amsterdam. Building on the successful launch event in 2019 we will once again be connecting synbio investors, academics and innovators to commercial end market customers across a variety of verticals. Across three days it will link science and technology to business and is committed to turning potential into reality and building a better, green world,” said Luke Upton, Editor and Co-Founder of SynBio Markets.

This event brings together stakeholders from across all facets of commercial biotechnology, blending innovators and academia with investors and commercial end market customers.  Thompson will be joining an impressive lineup of industry leaders to discuss the commercial opportunities and potential of synthetic biology to reshape and strengthen economies and commercial relationships.

“I am honored to have been selected by SynBio Markets,” said Thompson.  “I look forward to the opportunity to share Kraig Labs’ vision and insight on how our technology, and the technological innovations of others in this field, will change the commercial landscape with powerful products and environmentally friendly production methods.  We are one of the early innovators in this field and we are proud to have plowed a road which other companies are now following.  I want to thank the entire SynBio Markets team for their leadership in organizing this important event.”

To learn more about this important event in the commercialization of leading edge biotechnology, please visit www.synbiomarkets.com

On April 16 at 4:30pm ET, the Company will be revealing a significant scientific breakthrough in spider silk technology during an online press conference.  All interested parties can view this live event by going to www.kblbinvestors.com

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com